Recent developments include quarterly earnings call transcripts for Q2, Q3, and Q4 2026, providing detailed updates on financial performance and business operations. Analyst coverage and news articles have discussed revenue figures, earnings results, and stock performance trends.

• Accuray released its Q4 2026 earnings call transcript detailing recent financial results and business updates [N1].
• The Q3 2026 earnings transcript provided insights into operational progress and financial metrics [N2].
• Q2 2026 earnings call transcript highlighted ongoing business developments and financial performance [N3].
• BTIG maintained a buy recommendation for Accuray in November 2025, reflecting analyst confidence at that time [N4].
• In Q4 2025, Accuray reported revenues of $128 million and break-even earnings, indicating a notable operational milestone [N6][N8].
• News coverage in August 2025 noted a decline in stock price following Q4 earnings with revenues down year-over-year [N5].

The company maintains liquidity with a current ratio above 1 and cash reserves of over $40 million as of mid-2026. Regular quarterly earnings calls and analyst coverage indicate active investor engagement and operational transparency. The break-even earnings reported in Q4 2025 demonstrate points of operational progress.

Accuray reported a net loss of $49.2 million for fiscal year 2026, indicating ongoing profitability challenges. The cash ratio of 0.22 suggests limited immediate cash coverage relative to current liabilities. Revenue and earnings have shown variability, with some quarters reporting losses or break-even results, highlighting execution risks and market pressures.

Accuray operates in the medical technology sector, likely focusing on specialized equipment or solutions. The availability of detailed earnings calls and consistent SEC filings suggests a business with established operations and ongoing investor communication. However, specific competitive advantages or barriers to entry are not explicitly detailed in the available disclosures.

• Profitability Risk: The company reported a significant net loss for fiscal year 2026, indicating challenges in achieving sustained profitability.
• Liquidity Risk: While the current ratio is 1.5, the cash ratio is relatively low at 0.22, which may constrain short-term liquidity flexibility.
• Market and Execution Risk: Variability in quarterly earnings and revenue performance suggests exposure to market demand fluctuations and operational execution risks.

• Accuray Inc is a publicly traded company with ticker ARAY.
• The latest available SEC filing is a 10-K filed on 2026-08-27 covering fiscal year ending 2026-06-30 [S1].
• The company reported cash and cash equivalents of $40.6 million as of 2026-06-30 [S1].
• Current assets were $287.8 million and current liabilities were $191.4 million as of 2026-06-30, resulting in a current ratio of 1.5 and a cash ratio of 0.22 [S1].
• Net income for fiscal year ending 2026-06-30 was a loss of $49.2 million [S1].
• Basic earnings per share for fiscal year ending 2026-06-30 was -$0.40 [S1].
• Diluted earnings per share for the quarter ending 2025-12-31 was -$0.11 [S2].
• The company has recent quarterly earnings call transcripts for Q2, Q3, and Q4 2026, providing detailed business updates [N1][N2][N3].
• In Q4 2025, Accuray reported break-even earnings and revenue of $128 million [N6][N8].
• There has been analyst coverage including a maintained buy recommendation by BTIG in November 2025 [N4].
• Recent news coverage includes detailed earnings call transcripts and financial performance commentary from 2025 through 2026 [N1][N2][N3][N4][N5][N6][N7][N8].